Bayer to discontinue the LIPLONG study Bayer Schering Pharma AG, Germany has announced an independent Data Security and Monitoring Plank offers completed an interim evaluation of a stage II trial of the business’s long-acting recombinant aspect VIII, BAY79-4980. The DSMB figured the study will never be able to obtain the predetermined efficacy endpoint . No basic safety concerns were raised is caverta as effective as viagra click here . As a complete consequence of the DSMB results and recommendation, Bayer has made a decision to discontinue the study. While we are disappointed with the results of the evaluation, we remain focused on developing our long-performing recombinant element VIII compounds, stated Kemal Malik, M.D., person in the Board of Administration of Bayer Schering Pharma AG and Mind of Global Development.